Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223

OBJECTIVE: Radium-223(223Ra) is indicated for patients (p) with metastatic castration resistant prostate cancer (mCRCP). OBJECTIVES: The aim of this study was to evaluate the role of baseline clinical variables associated with overall survival (OS) and toxicity of 223Ra. Its purpose was to identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Vidal, Monica, Delgado, Alejandro, Martinez, Carlos, Correa, José Jaime, Durango, Isabel Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Urologia 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239273/
https://www.ncbi.nlm.nih.gov/pubmed/32213206
http://dx.doi.org/10.1590/S1677-5538.IBJU.2019.0343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239273/
https://www.ncbi.nlm.nih.gov/pubmed/32213206
http://dx.doi.org/10.1590/S1677-5538.IBJU.2019.0343

Ejemplares similares